CDNA$19.44
$19.1
Chart
Performance
Key Stats
AI CDNA Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutralCareDx (CDNA) presents a mixed investment profile. While it operates in a growing niche with positive earnings surprises recently, its long-term performance has been significantly negative. Technicals indicate a strong downtrend, suggesting caution is warranted for short-term traders, while long-term investors may find value if the company can reverse its performance trend.
Thematic
CareDx is positioned within the growing field of transplant diagnostics, benefiting from advancements in cell-free DNA testing and patient management solutions. The increasing demand for organ transplantation and the need for post-transplant monitoring create a favorable thematic backdrop.
Fundamental
CareDx shows recent positive earnings surprises and revenue growth, but historical financial data reveals significant losses and volatile performance. The balance sheet appears relatively stable with manageable debt, but free cash flow generation has been inconsistent.
Technical
The technical indicators for CareDx show a strong downtrend across multiple timeframes. The stock is trading well below its 52-week high, and moving averages are generally bearish, suggesting prevailing downward price pressure.
| Factor | Score |
|---|---|
| Healthcare Technology Advancement | 85 |
| Aging Population & Chronic Diseases | 75 |
| Market Penetration & Competition | 60 |
| Regulatory Landscape | 70 |
| Company Specific Initiatives | 60 |
| Factor | Score |
|---|---|
| Valuation | 70 |
| Profitability | 80 |
| Growth | 50 |
| Balance Sheet Health | 95 |
| Cash Flow | 60 |
| Earnings Per Share (EPS) Trend | 85 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 35 |
| Support & Resistance | 40 |
| Volume Analysis | 50 |
| Price Action vs. Peers | 20 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Positive Earnings Surprises
The company has consistently surpassed EPS estimates in recent quarters, with a significant positive surprise of 1300.0% in Q4 2024 and 273.61% in Q3 2024. This indicates strong operational execution and potentially underestimated earnings potential.
Improving Cash Position
Cash flow from operations has turned positive in the latest reported annual period (2024, $38.05M), and the company's cash equivalents stood at $114.69M at the end of 2024Q4, providing a buffer for operations and potential investments.
Bearish Points (7)
Significant Short-Term Decline
The stock has experienced substantial price declines over various short-term periods, with a 1-month performance of -33.49% and a 6-month performance of -43.28%, indicating recent negative market sentiment and price weakness.
Volatile Valuation Metrics
The P/E ratio has been highly volatile and negative in recent years (e.g., -3.7 in 2023, -9.3 in 2022), and the Price-to-Sales ratio for 2021 was significantly higher (8.5) than current levels, suggesting past overvaluation or significant business changes.
Calendar
August 2025
7
Next Earnings Date
H: $0.14
A: $0.12
L: $0.10
H: 91.78M
A: 90.67M
L: 89.50M
Profile
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI, a transplant quality tracking software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
Seasonals
Price Target
27.50 USD
The 39 analysts offering 1 year price forecasts for CDNA have a max estimate of 40.00 and a min estimate of 19.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Global leader in DNA sequencing and array-based technologies, fundamental to genomics research and applications.
Weight: 90
Largest provider of scientific instrumentation, reagents, and consumables critical for genomic research and analysis, including sequencers and PCR systems.
Weight: 88
Diversified science & technology innovator with major life sciences and diagnostics segments, offering genomic tools and instrumentation through brands like IDT and Beckman Coulter.
Weight: 85
Develops and manufactures advanced sequencing systems for long-read DNA sequencing, crucial for comprehensive genomic studies.